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Edited by Hans-Dieter KlenkAbstract The HIV-1 transactivating factor (Tat) acts as an
extracellular cytokine on target cells, including endothelium.
Here, we report about the Tat-antagonist capacity of chemically
sulfated derivatives of the Escherichia coli K5 polysaccharide.
O-sulfated K5 with high sulfation degree (K5-OS(H)) and N,O-
sulfated K5 with high (K5-N,OS(H)) or low (K5-N,OS(L))
sulfation degree, but not unmodiﬁed K5, N-sulfated K5, and
O-sulfated K5 with low sulfation degree, bind to Tat preventing
its interaction with cell surface heparan sulfate proteoglycans,
cell internalization, and consequent HIV-LTR-transactivation.
Also, K5-OS(H) and K5-N,OS(H) prevent the interaction of Tat
to the vascular endothelial growth factor receptor-2 on endothe-
lial cell (EC) surface. Finally, K5-OS(H) inhibits avb3 integrin/
Tat interaction and EC adhesion to immobilized Tat. Conse-
quently, K5-OS(H) and K5-N,OS(H) inhibit the angiogenic
activity of Tat in vivo. In conclusion, K5 derivatives with distinct
sulfation patterns bind extracellular Tat and modulate its
interaction with cell surface receptors and aﬀect its biological
activities. These ﬁndings provide the basis for the design of
novel extracellular Tat antagonists with possible implications in
anti-AIDS therapies.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The transactivating factor of the HIV-1 virus (Tat) is re-
leased from HIV-1 infected cells [1]. Extracellular Tat (xcTat)
elicits diﬀerent biological activities in several cells types in-
cluding endothelium, thus contributing to the onset of AIDS-
associated pathologies [2,3].
The mechanisms by which xcTat stimulates target cells are
manifold. Tat binds cell-surface heparan sulfate proteoglycans
(HSPGs), being then internalized in a bioactive form to reach
the nucleus and transactivate cellular and viral genes [4].
Commercial heparin binds xcTat and inhibits its interaction
with cell-associated HSPGs, its cellular uptake and transacti-
vation [4–6]. Tat/heparin interaction requires a proper tri-
dimensional conformation of the protein and at least some
2-O-, 6-O-, and N-positions of the glycosaminoglycan (GAG)
to be sulfated [7]. Sulfated groups of heparin bind to a stretch
of positively charged amino acid residues present in the basic
domain of Tat [5]. Other polyanionic compounds such as
suramin and its derivatives, dextrin-2-sulfate, and pentosan
polysulfate bind Tat and inhibit its interaction with cell surface
HSPGs and consequent biological activities [3] (and reference
therein).
xcTat also binds various signaling receptors in target cells,
including the vascular endothelial growth factor receptor (Flk-
1/KDR) [8] and integrins [2,9]. In endothelial cells (ECs), the
interaction of xcTat with KDR and/or avb3 integrin mediates
Tat-induced cell adhesion, proliferation and chemotaxis in
vitro and neovascularization and vascular permeability in vivo
[2]. Despite the importance of these observations about the
multiple mechanisms of action of xcTat, only a few data, if
any, are available about the possible eﬀects of heparin-like Tat
antagonists on these interactions.
The capsular K5 polysaccharide from Escherichia coli has
the same structure [!4)-b-D-GlcA-(1! 4)-a-D-GlcNAc-
1(1!]n as the heparin precursor N-acetyl heparosan [10] in
which GlcA is glucuronic acid and GlcNAc is N-acetyl-
glucosamine. Previous studies demonstrated the possibility to
generate sulfated K5 derivatives by chemical sulfation in N-
and/or O-positions [11]. Interestingly, K5 derivatives with de-
ﬁned sulfation patterns interact with the angiogenic ﬁbroblast
growth factor-2 (FGF-2) and FGF-8, aﬀecting their receptorblished by Elsevier B.V. All rights reserved.
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Also, sulfated K5 derivatives inhibit the replication of HIV in
T cells and macrophages by preventing virion attachment and
entry [14].
On these bases, a panel of N-, O-, and N,O-sulfated K5
derivatives with diﬀerent sulfation patterns were evaluated for
their ability to bind Tat, to aﬀect its interaction with cell sur-
face receptors and its biological activity in vitro and in vivo.
The results demonstrate that selective sulfation patterns confer
diﬀerent Tat antagonist capabilities to K5 derivatives.2. Materials and methods
2.1. Reagents
86 amino acid HIV-1 Tat was expressed and puriﬁed by E. coli as
glutathione S-transferase fusion protein (GST–Tat) or as GST–Tat
fused to the green ﬂuorescent protein (GST–Tat–GFP) [6]. GST and
GFP moieties do not interfere with the heparin-binding capacity, long
terminal repeat (LTR)-transactivating activity and angiogenic activity
of Tat [15]. Synthetic Tat and its biotinilated form (bTat) were from
Tecnogen (Caserta, Italy). The anti-avb3 monoclonal LM 609 antibody
was from Chemicon International (Temecula, CA). The anti-KDR
antibody was from Prof. H.A. Weich, Max Plank Institute, Germany.
Human recombinant vascular endothelial growth factor (VEGF)165
was from Calbiochem Biochemicals (La Jolla, CA). The homoge-
neously sized 24-mer heparin was provided by U. Lindahl (Uppsala
University, Sweden). K5 polysaccharide derivatives were obtained by
N-deacetylation/N-sulfation and/or O-sulfation of a single batch of K5
polysaccharide [12].
2.2. BIAcore binding assays
A BIAcore X apparatus (BIAcore Inc, Piscataway, NJ) was used.
Surface plasmon resonance (SPR) was exploited to measure changes in
refractive index caused by the ability of the diﬀerent GAGs to bind to
GST–Tat immobilized to a BIAcore sensorchip. To this purpose, 50
lg/ml of GST–Tat were allowed to react with a ﬂow cell of a CM5
sensorchip that was previously activated with 50 ll of a mixture of 0.2
M N-ethyl-N0-(3-dimethylaminopropyl)carbodiimide hydrochloride
and 0.05 M N-hydroxysuccinimide. These experimental conditions
allowed the immobilization of 10 281 resonance units (RUs), corre-
sponding to approximately 0.3 pmol of GST–Tat. Similar results were
obtained for the immobilization of GST, here used as a negative
control and for blank subtraction. Increasing concentrations of the
various K5 derivatives in 10 mM HEPES, 150 mM NaCl, 3.4 mM
EDTA, 0.005% surfactant P20, pH 7.4 (HBS) were then injected over
the GST–Tat or GST surfaces for 4 min. (to allow their association
with immobilized proteins) and then washed until dissociation was
observed. After every run, the sensorchip was regenerated by injection
of HBS containing 2.0 M NaCl. No diﬀerence in the binding param-
eters was found when sensorgrams obtained from the injection of K5
derivatives on GST surface were used as a blank to correct for possible
aspeciﬁc binding (data not shown). In parallel experiments, SPR was
exploited to evaluate the capacity of O-sulfated K5 with high degree of
sulfation (K5-OS(H)) to compete with sensorchip-immobilized heparin
for the binding to free GST–Tat protein. To this purpose, heparin was
biotinilated on its reducing end and a ﬂow cell of an F1 sensorchip was
activated with streptavidin. Then, biotinilated heparin was allowed to
react with the streptavidin-coated sensorchip as already described [15].
GST–Tat alone or in the presence of increasing concentrations of K5-
OS(H) was then injected over the heparin surface for 5 min (to allow
the association of the protein with heparin) and then washed until
dissociation was observed. The SPR signal was expressed in terms of
RUs.
2.3. Preparation of 3H-labeled heparin and GST–Tat aﬃnity
chromatography
3H-heparin was prepared as described [16] and loaded (50 lg/300 ll)
onto a 80 ll GST–Tat–glutathione–agarose column in the presence of
the various GAGs. The column was then washed with PBS and eluted
with 2.0 M NaCl. Radioactivity in the eluate was measured in a liquid
scintillation counter.2.4. Cell cultures
Wild type and HSPG-defective A745 CHO-K1 cells [17] (provided
by J.D. Esko, University of Birmingham, AL) were grown in Ham’s F
12 medium (Gibco, Grand Island, NY) with 10% FCS (Gibco). HL3T1
cells, derived from HeLa cells, contain integrated copies of pL3CAT
plasmid in which the chloramphenicol acetyltransferase (CAT) bacterial
gene is driven by HIV-1 LTR [18]. They were grown in Dulbecco’s
modiﬁed Eagle’s medium (Gibco) with 10% FCS. Porcine aortic ECs
(PAECs) and KDR-transfected PAECs (PAEC/KDRs) [19] were
grown in Ham’s F-12 medium with 10% FCS and 2% glutamine.
Transformed fetal bovine aortic endothelial GM 7373 cells [20] were
grown in Eagle’s minimal essential medium (Gibco) with 10% FCS,
vitamins, essential and non-essential amino acids. Human umbilical
vein ECs (HUVECs) were from Biowhittaker (Walkersville, MA) and
cultured in EGM-2 medium (Biowhittaker).
2.5. Cell-binding assay of bTat
Subconﬂuent cultures of the diﬀerent cell lines in 96-wells plates were
incubated for 2 h at 4 C in PBS containing 0.1 mg/ml CaCl2, 0.1 mg/
ml MgCl2, 0.1% gelatin and bTat (600 ng/ml) in the presence of the
diﬀerent GAGs. At the end of incubation, Chinese hamster ovary
(CHO) cells and PAECs were washed with PBS alone or containing 2.0
M NaCl, respectively. The amount of cell-associated bTat was detected
with horseradish peroxidase-labeled avidin (1/1500) and chromogen
substrate ABTS (Kirkgaard & Perry Laboratories, Gaithersburg,
MD).
2.6. HIV-LTR transactivation and Tat internalization assays
The two assays were performed on HL3T1 cells exactly as described
[6].
2.7. Cell-free avb3 integrin/GST–Tat interaction and cell adhesion assay
Human avb3 integrin puriﬁcation, cell-free avb3 integrin/GST–Tat
interaction and cell adhesion assay with GM 7373 ECs were performed
as previously described [21].
2.8. Chick embryo chorioallantoic membrane assay
Chick embryo chorioallantoic membrane (CAM) assay was per-
formed as described [22]. Brieﬂy, a window was opened in the egg shell
of three-day-old fertilized chicken eggs. At day 8, gelatin sponges
containing Tat in the absence or in the presence of K5 derivatives were
implanted on the CAMs (10 embryos per group). At day 12, the an-
giogenic response was scored by counting the number of vessel that
surround the sponge.3. Results
3.1. Interaction of sulfated K5 derivatives with Tat protein
Unmodiﬁed K5 and sulfated K5 derivatives were evaluated
for their ability to bind Tat by using the BIAcore technology.
As shown in Fig. 1A, when injected at 30 nM, K5-OS(H) and
N,O-sulfated K5 with high degree of sulfation (K5-N,OS(H))
bind to GST–Tat immobilized onto a BIAcore sensorchip with
high capacity (200–250 RU bound at the end of the injection
phase). Under the same experimental conditions, N,O-sulfated
K5 with low degree of sulfation (K5-N,OS(L)) and heparin
(data not shown) were less eﬀective (60–70 RU bound),
whereas unmodiﬁed K5, N-sulfated K5 (K5-NS), and O-
sulfated K5 with low degree of sulfation (K5-OS(L)) did not
show a signiﬁcant binding capacity also when tested at 300 lM
(data not shown). Speciﬁcity of the interaction was demon-
strated by the lack of binding of K5-N,OS(H) and K5-OS(H)
to a GST–coated sensorchip (Fig. 1B).
Increasing concentrations of K5-N,OS(H) (Fig. 1C), K5-
N,OS(L), K5-OS(L), K5-OS(H) or heparin (not shown) where
injected over the GST–Tat surface to evaluate the binding
parameters (Table 1). In some experiments, the association
phase of GAG/GST–Tat interaction was allowed to proceed to
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Fig. 1. Interaction of K5 derivatives with Tat: (A) K5 derivatives were injected at 30 nM over a BIAcore sensorchip containing GST–Tat. From top
to bottom: K5-OS(H), K5-N,OS(H), K5-N,O-S(L), K5-OS(L), K5 and K5-NS. (B) K5-OS(H) (straight line) or K5-N,OS(H) (dotted line) (both at 30
nM) were injected over GST–Tat or GST surfaces. (C) Increasing concentrations of K5-NOS(H) were injected over a GST–Tat surface. (D) GST–Tat
(125 nM) was injected over a ﬂow cell of a BIAcore sensor chip containing streptavidin plus immobilized biotinilated heparin in the presence of
increasing concentrations of K5-OS(H) (d). In parallel experiments, GST–Tat (125 nM) was injected alone and allowed to interact with the heparin
surface for 5 min. Then, K5-OS(H) (100 nM) was injected (s). The response (in RU) in the diﬀerent experimental conditions was recorded at the end
of injections and plotted as a function of K5-OS(H) concentration.
Table 1
Binding parameters of the interaction of K5 derivatives to GST–Tat immobilized to a BIAcore sensorchip
Sample Molecular weight (kDa) Association rate (kass) (1/Ms) Dissociation rate (kdiss) (1/s) Dissociation constant (Kd) (nM)
Kinetics Equilibrium
K5 30.0 n.d. n.d. n.d. n.d.
K5-NS 15.0 n.d. n.d. n.d. n.d.
K5-OS(L) 14.0 n.d. n.d. n.d. n.d.
K5-OS(H) 11.0 2.53 1.2 106 3.97 2.2 103 2.0 7.05
K5-N,OS(L) 13.0 3.4 0.5 105 6.28 2.5 103 18.0 69.9
K5-N,OS(H) 15.0 4.9 2.1 105 6.16 3.0 104 10.0 16.7
Heparin 13.6 1.4 1.1 105 2.83 0.8 103 20.0 16.0
Binding parameters were calculated by the non-linear curve ﬁtting software package BIAevaluation 3.2 using a single site model with correction for
mass transfer. Only sensorgrams whose ﬁtting gave values of X2 close to 10 were used [29]. Association and dissociation rates were calculated
separately using low (1–5 nM) and high (30–300 nM) concentrations of K5 derivatives, respectively [30]. Each data is the mean S.E.M. of 3–4
independent determinations. Dissociation constant (Kd) was instead derived from the kdiss/kass ratio (kinetics). Alternatively, data from the equi-
librium binding between GAGs and GST–Tat were used to calculate an aﬃnity value independent of the kinetics of binding (equilibrium).
The correlation coeﬃcient of the linear regression of the equilibrium binding data was always higher than 0.8 (n.d.: non detectable).
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value independent of the kinetics of binding. This analysis
demonstrates that GST–Tat/heparin interaction occurs with a
Kd equal to 16 nM, a value consistent with our kinetics anal-
ysis (20 nM) and with previous determinations obtained with
diﬀerent experimental approaches [6,15]. Interestingly, K5-
OS(H) binds immobilized GST–Tat with an aﬃnity that is 5–
10 times higher than that of the other GAGs tested (Table 1).
K5 derivatives are expected to act as free antagonist that
interfere with the binding of exTat to cell-surface associated
HSPGs. On this basis, we evaluated the capacity of free K5-
OS(H) to sequester Tat in the mobile phase thus inhibiting its
interaction with heparin immobilized onto a BIAcore sensor-
chip, an experimental condition that resembles Tat interaction
with cell-surface HSPGs [15]. As shown in Fig. 1D, when in-
jected together with Tat on the heparin surface, K5-OS(H)prevents Tat/heparin interaction in a dose-dependent manner.
In parallel experiments, Tat was allowed to reach a binding
equilibrium with the heparin surface. Then, K5-OS(H) was
injected on the sensorchip. Under these experimental condi-
tions, K5-OS(H) disrupts the already established Tat-heparin
complex (Fig. 1D).
Next, sulfated K5 derivatives were assessed for their capacity
to compete with 3H-heparin for the binding to Tat. K5-OS(H),
K5-N,OS(L), K5-N,OS(H) and unlabeled heparin competed
with 3H-heparin for the binding to immobilized GST–Tat. In
contrast, unmodiﬁed K5, K5-NS, and K5-OS(L) did not exert
a signiﬁcant competition when tested at 10 lg/ml (Fig. 2).
3.2. Eﬀect of K5 derivatives on Tat/HSPG interaction
The capacity of sulfated K5 derivatives to aﬀect xcTat/
HSPG interaction in CHO-K1 cells was then evaluated. A745
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Fig. 2. Competition binding assays: GST–Tat–glutathione–agarose
columns were loaded with 3H-heparin in the presence of K5 (s), K5-
NS (), K5-OS(L) (,), K5-OS(H) (.), K5-N,OS(L) (n), K5-N,OS(H)
(m) or heparin (d). Columns were washed and bound radioactivity
measured. Each point is the mean of 3 determinations in duplicate.
S.E.M. never exceeded 12% of the mean value.
174 C. Urbinati et al. / FEBS Letters 568 (2004) 171–177CHO-K1 cell mutants defective for HSPG synthesis were used
as a control for non-speciﬁc Tat interaction [4]. bTat binds
CHO-K1 cells and a 2.0 M NaCl wash reduces the amount of
cell surface-bound Tat to values similar to those measured in
HSPG-deﬁcient A745 CHO-K1 mutants (Fig. 3A). This con-
ﬁrms that the observed binding is mainly due to bTat/HSPGs
interaction [23,24]. Heparin, K5-OS(H), K5-N,OS(L), and K5-
N,OS(H) were all able to inhibit Tat/HSPG interaction in
CHO-K1 cells. Unmodiﬁed K5, K5-NS, and K5-OS(L) were
instead ineﬀective (Fig. 3B).**
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Fig. 3. Eﬀect of K5 derivatives on Tat binding to cell surface HSPGs, cell i
(A745) and wild type CHO-K1 cells (W.T.) were incubated with bTat and th
bars). (B) Wild type CHO-K1 cells were incubated with bTat in the absence
amount of cell-associated bTat was measured. In panel B, data are expressed
bar represents the meanS.E.M. of three determinations in duplicate. Stud
GFP (400 ng/ml) in the absence ()) or in the presence of the indicated GA
evaluated. Data are expressed as percent of GST–Tat-GFP internalized in
determinations in duplicate. Student’s t-test: *, P < 0:001. (D) HL3T1 cells w
NS (), K5-OS(L) (,), K5-OS(H) (.), K5-N,OS(L) (n), K5-N,OS(H) (m),
devoid of the GST or GFP moiety in the absence or in the presence of K5-OS
antigen. Data are expressed as percent of the activity measured in the absenc
S.E.M. never exceeded 13% of the mean value. Student’s t-test: **, P < 0:01Tat/HSPG interaction leads to Tat internalization and gene
transactivation [4]. In agreement with surface binding experi-
ments performed in CHO-K1 cells, heparin, K5-OS(H), K5-
N,OS(L), and K5-N,OS(H) inhibited the internalization of
GST–Tat–GFP in HL3T1 cells (Fig. 3C). Accordingly, K5-
OS(H), K5-N,OS(L), and K5-N,OS(H) inhibited the LTR-
transactivating activity of GST–Tat in a dose-dependent
manner with a potency similar to that shown by heparin
(Fig. 3D). Unmodiﬁed K5, K5-NS, and K5-OS(L) were inef-
fective in both the assays (Fig. 3C and D).
Finally, K5-OS(H) also inhibits LTR transactivation exerted
by exogenously added synthetic Tat in HL3T1 cells, ruling out
a possible aspeciﬁc action of K5 derivatives on the GST or
GFP moieties of the Tat fusion proteins used in the previous
assays (Fig. 3D). On the contrary, K5-OS(H) did not aﬀect
HIV-LTR transactivation exerted by native Tat produced
endogenously by HL3T1 cells following transient transfection
with an expression vector harboring the HIV-1 Tat cDNA
(data not shown), supporting the hypothesis of an extracellular
mechanism of action of K5 derivatives.
3.3. Eﬀect of K5 derivatives on Tat/KDR interaction
Binding and activation of KDR is required for Tat-induced
EC proliferation and chemotaxis in vitro and for neovascu-
larization and vascular permeability in vivo [8,25]. bTat binds
the surface of KDR-overespressing PAEC/KDR cells with
high capacity when compared to parental cells (Fig. 4A). The
binding resists a 2.0 M NaCl wash but is prevented by sura-
min, anti-KDR antibodies, and a molar excess of VEGF165, in
keeping with an high aﬃnity binding to KDR receptor [8]. K50
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Fig. 4. Eﬀect of K5 derivatives on Tat/KDR interaction. (A) Parental PAE cells and PAEC/KDR cells were treated with bTat in the absence (black
bars) or in the presence of suramin (300 lg/ml) (white bars), anti-KDR antibodies (200 lg/ml) (grey bar) or recombinant VEGF165 (3 lg/ml) (crossed
bar). (B) PAEC/KDRs were incubated with bTat in the in the absence ()) or in the presence of the indicated GAGs (3 lg/ml). Then, cells were
washed with PBS containing 2 M NaCl and the amount of cell-associated bTat was measured. Non speciﬁc binding was measured in the presence of
suramin [5]. In panel B data are expressed as percent of bTat bound to cells in the absence of GAGs. Each bar represents the meanS.E.M. of three
determinations in duplicate. Student’s t-test: **, P < 0:01.
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xcTat/KDR interaction in PAEC/KDR cells. When tested at 3
lg/ml, only K5-OS(H) and K5-N,OS(H) prevented the inter-
action of Tat with PAEC/KDR cells. Under the same experi-
mental conditions, K5-N,OS(L) and heparin did not exert any
inhibitory eﬀect (Fig. 4B) despite their ability to bind to Tat
(see above).Fig. 5. Eﬀect of K5 derivatives on Tat/avb3 interaction. GM 7373 cells
(panel A) or HUVE cells (panel B) were allowed to adhere onto non
tissue culture plates coated with BSA (grey bar), GST–Tat (black bars)
or VN (white bars) (all at 20 lg/ml) in the absence ()) or in the
presence of the indicated GAGs (1.5 lg/ml) or of the anti-avb3
monoclonal antibody LM609 (100 lg/ml). The number of adherent
cells were then evaluated. Arrow: cells adherent to wells coated with
GST protein (20 lg/ml). Each bar represents the mean S.E.M. of 3–6
determinations in duplicate. Student’s t-test: **, P < 0:01. (C) Puriﬁed
human avb3 was incubated onto wells coated with BSA or GST–Tat in
the absence ()) or in the presence of the indicated GAGs (300 lg/ml).
Then, plastic-bound proteins were extracted and analyzed by Western
blotting with anti-b3 antibodies.3.4. Eﬀect of K5 derivatives on Tat/avb3 integrin interaction
xcTat interacts with avb3 integrin receptors present on ECs
[2,9]. Endothelial GM 7373 cells express avb3 integrin [21] and
adhere to immobilized GST–Tat, but not to BSA or GST
(Fig. 5A), in a avb3-dependent manner, as demonstrated by the
inhibition exerted by the monoclonal anti-avb3 LM609 anti-
body (Fig. 5A). K5 derivatives were then evaluated for their
ability to aﬀect GM 7373 cell adhesion to immobilized GST–
Tat. When tested at 1.5 lg/ml, only K5-OS(H) prevented the
adhesion of ECs to GST–Tat-coated plastic. Again, despite
their Tat-binding capacity, K5-N,OS(L), K5-N,OS(H) and
heparin did not exerted any inhibitory eﬀect when tested under
the same experimental conditions (Fig. 5A). Also, K5-OS(H)
did not inhibit the avb3-mediated GM 7373 cell adhesion to
vitronectin (VN) (Fig. 5A), thus supporting the speciﬁcity of
its Tat-antagonist activity. Finally, the avb3-antagonist activity
of K5-OS(H) was not restricted to GM 7373 cells, as demon-
strated by its capacity to inhibit also HUVE cell adhesion to
immobilized Tat (Fig. 5B).
Puriﬁed avb3 integrin binds to immobilized GST–Tat
(Fig. 5C). Speciﬁcity of the interaction is demonstrated by the
lack of binding of avb3 to immobilized BSA. Preincubation of0
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Fig. 6. Eﬀect of K5 derivatives on Tat-induced angiogenesis in the
chick embryo CAM. CAMs were implanted with gelatin sponges ad-
sorbed with vehicle (grey bar) or with GST–Tat (400 ng) (black bars) in
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avb3 whereas unmodiﬁed K5 and heparin were ineﬀective
(Fig. 5C). Taken together, the data demonstrate that K5-
OS(H) inhibits EC adhesion to immobilized Tat by preventing
avb3 integrin interaction.
3.5. K5 derivatives inhibit the angiogenic activity of Tat protein
Tat protein exerts a potent angiogenic response in vivo by
engaging both KDR and avb3 integrin receptors [2] (and ref-
erences therein). Since K5-OS(H) and K5-N,OS(H) interfere
with these interactions, they were evaluated for their ability to
inhibit Tat-induced neovascularization in the CAM assay
[22]. Both K5-OS(H) and K5-N,OS(H) exerted a signiﬁcant
inhibition whereas heparin, unmodiﬁed K5, and the other K5
derivatives tested were ineﬀective (Fig. 6).4. Discussion
HIV-1 Tat, originally viewed as a viral transactivating factor
with an intracellular mechanism of action, can act also as an
extracellular growth factor endowed with heparin-binding ca-
pacity. On this basis, polyanionic compounds have been as-
sessed as potential xcTat antagonists [3].
In the present paper, we evaluated the Tat-binding and an-
tagonist capacity of a series of K5 derivatives with diﬀerent
sulfation patterns. A complete N-sulfation of glucosamine
(GlcN) residues characterized the N- and N,O-sulfated deriv-
atives whereas O-sulfation resulted in the almost complete 6-
O-sulfation of GlcN residues in all the O- and N, O-sulfated
derivatives that diﬀered therefore for the extent of O-sulfation
in the other positions [12].
Sulfated K5 derivatives act as xcTat-antagonists by mimick-
ing heparin. Indeed, deﬁned sulfated K5 derivatives interact
with Tat, compete with 3H-heparin for the binding to immobi-
lized Tat, and prevent Tat interaction with cell-surface HSPGs.
When compared to heparin, K5-N,OS(H) displays a similar
binding aﬃnity (see Table 1) but a higher binding capacity [60
and 250 RU bound to the Tat surface, respectively, Fig. 1],
despite their similar size. Previous observations had shown that
a single heparin chain is able to bind up to 6 molecules of Tat
with a cooperative interaction [6]. Thus, the diﬀerent binding
capacity between K5-N,OS(H) and heparin may be explained
by the possibility that the highly sulfated, virtually homoge-
neous K5-N,OS(H) chain contains an even higher number of
high aﬃnity binding sites than the more heterogeneous heparin
chain. Further studies are required to clarify this point.
Previous studies demonstrated that Tat/heparin interaction
requires at least some 2-O-, 6-O-, and N-positions to be
sulfated [7]. Non-sulfated K5 is devoid of any signiﬁcant Tat-
binding capacity, thus indicating that sulfate groups are
essential also for K5 derivative interaction with Tat. Accord-
ingly, only K5-OS(H) and K5-N,OS(H) [SO3 /COO
 equal to
3.8 for both compounds], and K5-N,OS(L) [SO3 /COO
 equal
to 1.7] interact with Tat with high aﬃnity. Among the
Tat-binding compounds, K5-OS(H) consists of the virtually
homogeneous repeat of GlcA2,3SO3 –GlcNAc3,6SO

3 disac-
charide units and most of K5-N,OS(H) sequences are
represented by GlcA2,3SO3 –GlcNSO

3 ,6SO

3 , whereas
K5-N,OS(L) is mainly formed by GlcA-GlcNSO3 ,6SO

3
disaccharide units [12]. These data indicate that both thedegree of sulfation and charge distribution modulate the Tat-
binding capacity of sulfated K5 derivatives completely com-
posed of GlcA–GlcN sequences.
The capacity of K5-N,OS(L) to bind Tat protein indicates
that disulfated GlcNSO3 ,6SO

3 residues alternated with non-
sulfated GlcA residues are suﬃcient for a signiﬁcant interac-
tion. This observation, together with the lack of binding
capacity of K5-NS and K5-OS(L) derivatives (consisting
mostly of the homogenous repeats of GlcA–GlcNSO3 and
GlcA–GlcNAc6SO3 disaccharide units, respectively), indicate
that in the case of lower sulfated compounds the position of
the sulfate groups are important, being both N-sulfated and 6-
O-sulfated residues necessary for the interaction. The presence
of additional sulfated groups in GlcA residues, as it occurs in
K5-N,OS(H), does not seem to aﬀect the association/dissoci-
ation rates of the interaction, even though it exerts a dramatic
eﬀect on some of the Tat-antagonist activities of the derivative
in vitro and in vivo.
Interaction of xcTat with cell-associated HSPGs is required
for its internalization and transactivation [4]. In agreement
with their heparin-mimicking, Tat-binding capacity, K5-
OS(H), K5-N,OS(L), and K5-N,OS(H) prevented Tat uptake
and HIV-LTR transactivation in HL3T1 cells whereas K5,
K5-NS, and K5-OS(L) were ineﬀective.
However, xcTat exerts angiogenic activity in vivo that re-
ﬂects its capacity to interact with KDR and avb3 integrin re-
ceptors on EC-surface [2]. Diﬀerent regions of the Tat protein
appear to be involved in these interactions. The integrin rec-
ognition motif Arg–Gly–Asp is present in Tat and mediates
avb3 interaction [9] without playing any role in heparin/HSPG
[5] or KDR [8] interactions. In contrast, the heparin-binding,
basic domain of Tat contributes signiﬁcantly to integrin [23]
and KDR [8] interaction.
Here, we demonstrate that K5-OS(H) and K5-N,OS(H)
prevent the interaction of Tat with KDR. At variance, K5-
OS(H), but not K5-N,OS(H), inhibits the interaction of Tat
with avb3. In agreement with the tight cross-talk between ty-
rosine kinase angiogenic growth factor receptors and integrins
in intracellular signaling and angiogenesis, both K5 derivatives
suppressed the angiogenic activity of Tat. Interestingly, low
sulfated K5-N,OS(L) and heparin were unable to aﬀect KDR
and avb3 interactions despite their capacity to bind Tat with
high aﬃnity. Consequently, they did not exert any anti-an-
giogenic activity in vivo.
Taken together, our data indicate that the capacity of K5
derivatives to bind Tat thus preventing its interaction with cell
surface HSPGs is suﬃcient to aﬀect its cell internalization and
LTR-transactivating activity. However, this does not neces-
sarily result in a signiﬁcant Tat antagonist activity for diﬀerent
signaling receptors and for neovascularization. Also, the dif-
ferent capacity of K5-OS(H) and K5-N,OS(H) to aﬀect avb3
and/or KDR interaction indicates the possibility to dissociate
diﬀerent Tat antagonist activities by tailoring the distribution
of sulfate groups along the GAG chain. This dissociation may
depend on distinct interactions of the various K5 derivatives
with Tat protein that mask diﬀerent functional domains and/or
to a diﬀerent capacity of K5 derivatives to bind directly to Tat
receptors, as already demonstrated for the FGF-2/FGFR
system [26]. Further studies with K5 derivatives may shed new
lights on the mechanism(s) of action of xcTat.
Heparin binding to Tat is size dependent, being 5–6 sac-
charide residues the minimal structure required for a low af-
C. Urbinati et al. / FEBS Letters 568 (2004) 171–177 177ﬁnity interaction [6]. On the other hand, the reduction in size
of a GAG ameliorates its pharmacokinetics and its bioavail-
ability in the blood stream [27]. Relevant to this point, we
observed that a low molecular weight K5-N,OS(H) (4.8 kDa)
binds GST–Tat and inhibits its transactivating activity with
aﬃnity/potency that are comparable to those of the parent
compound (data not shown), thus suggesting the possibility to
reduce the size of K5 derivatives without losing their Tat-an-
tagonist activity. Also, K5-OS(H) and K5-N,OS(H) are en-
dowed with low anti-coagulant activity when compared to
heparin (Oreste P. and Zoppetti G., unpublished observation).
xcTat contributes to HIV replication associated with pri-
mary HIV infection, when synchronized virion replication
takes place [28]. K5-OS(H) and K5-N,OS(H) inhibit HIV
replication by preventing virion attachment and/or entry in T
cells and macrophages [14]. Also, K5-N,OS(H) is a potent
antagonist of FGF-2 [12] that contributes to the progression of
Kaposi’s sarcoma, an ipervascularized lesion frequently found
in male AIDS patients.
These observations, together with the results here reported,
suggest that sulfated K5 derivatives can be exploited for the
design of multi-target drugs able to prevent/retard HIV-
infection/AIDS progression and to cure AIDS-associated pa-
thologies, including Kaposi’s sarcoma.
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